Latest & greatest articles for geriatrics

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on geriatrics or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on geriatrics and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for geriatrics

1. Abdominal aorta aneurysm (AAA) screening of men aged 65

Abdominal aorta aneurysm (AAA) screening of men aged 65 Abdominal aorta aneurysm (AAA) screening of men aged 65 - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Abdominal aorta aneurysm (AAA) screening of men aged 65 Order Download: Key message Abdominal aortic aneurysm (AAA) is a weakening of the aortic wall resulting in an abnormal (...) dilatation of the abdominal aortic artery. AAAs bears the risk of rupture, which is a dramatic emergency condition with a high risk of death. In Norway, about 1% of all deaths among men older than 65 years are caused by AAA rupture. The mortality rate due to AAA rupture is approximately 75%, with about half of the deaths occurring before the patient reaches the hospital. The larger the AAA, the higher is the risk of rupture. Prevalence of AAA among men varies across countries from approx. 1.5-3

2020 Norwegian Institute of Public Health

2. The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial

The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) : 10.1016/j.jen.2020.04.011. Online ahead of print. The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial , , , , , PMID: 32690314 DOI: Item in Clipboard The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial Duygu Sönmez Düzkaya et al. J

2020 EvidenceUpdates

3. Evidence review on the benefits of physical activity for older people

of developing functional limitations or a decline in Basic Activities of Daily Living (BADL) disability 14 15 was reduced Institute of Public Health 6 by participation in physical activity 15 . Emerging evidence also highlights the positive impact of physical activity on the healthy ageing process, by improving QoL and increasing the odds of maintaining wellbeing in older age 16 . Finally, as the global population ages, the number of people living with cognitive impairment or dementia is expected (...) 18 19 . Growing evidence also reports that physical activity can improve cognitive function and, consequently, delay the progression of cognitive impairment in older adults 14 20 21 . Implications for Research and Policy Physical activity plays a key role in healthy ageing across the life cycle but especially in later years in the management of one’s health and wellbeing. The goal of public health is to decrease the time spent in ill- health as people age and ensure that an increase in life

2020 Institute of Public Health in Ireland

4. A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination with Oseltamivir in Elderly and NonElderly Adults Hospitalized with Influenza A Infection: OPAL study Full Text available with Trip Pro

efficacy). Pimodivir is a first-in-class antiviral for influenza A under development for these patients. Methods: Hospitalized patients with influenza A infection were randomized 2:1 to receive pimodivir 600 mg plus oseltamivir 75 mg or placebo plus oseltamivir 75 mg twice daily for 7 days in this phase 2b study. The primary objective was to compare pimodivir pharmacokinetics in elderly (aged 65-85 years) versus non-elderly adults (aged 18-64 years). Secondary endpoints included time-to-patient (...) -reported symptom resolution. Results: Pimodivir pharmacokinetic parameters in non-elderly and elderly patients were similar. Time-to-influenza symptom resolution was numerically shorter with pimodivir (72.45 hours) than placebo (94.15 hours). There was a lower incidence of influenza-related complications in the pimodivir group (7.9%) versus placebo group (15.6%). Treatment was generally well tolerated. Conclusions: No apparent relationship was observed between pimodivir pharmacokinetics and age. Our

2020 EvidenceUpdates

5. Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data Full Text available with Trip Pro

: alteplase; elderly; ischemic stroke; recombinant tissue-type plasminogen activator; thrombolysis. Figures Figure 1. 5 Estimated effect of alteplase vs… Figure 1. 13 Estimated effect of alteplase vs placebo on the odds of good stroke outcome… Figure 1. Estimated effect of alteplase vs placebo on the odds of good stroke outcome by time to treatment, patient age, and stroke severity. A , Time to treatment ( P =0.0203 for interaction). B , Patient age ( P =0.7383 for interaction). C , Stroke severity (...) JA, Lindsberg PJ, Ringleb PA, Wahlgren NG, Lees KR; VISTA Collaborators; SITS Collaborators Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010341c6046.doi: 10.1136/bmj.c6046 - - Show all 33 references Related information LinkOut - more resources Full Text Sources Research Materials Miscellaneous Full-text links [x] [x] Citation text Copy Download .nbib Format: Send To [x] Connect

2020 EvidenceUpdates

6. Effects of Whole-Body Vibration Training on the Physical Function of the Frail Elderly: An Open, Randomized Controlled Trial

Cite Abstract Objective: To investigate the feasibility and benefits of whole-body vibration (WBV) exercise as a safe and effective training tool for countering sarcopenia and age-related declines in mobility and function in the frail elderly. Design: An open, randomized controlled trial. Setting: Residential care facilities. Participants: Male and female volunteers (N=117; 82.5±7.9y). Interventions: After prescreening for contraindications, participants were randomly allocated to a control (...) Effects of Whole-Body Vibration Training on the Physical Function of the Frail Elderly: An Open, Randomized Controlled Trial Effects of Whole-Body Vibration Training on the Physical Function of the Frail Elderly: An Open, Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly

2020 EvidenceUpdates

7. Cost-effectiveness of a preventive self-care health management program for community-dwelling older adults: a randomised controlled trial

for community-dwelling older adults: a randomised controlled trial , , Affiliations Expand Affiliations 1 School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong. 2 School of Optometry, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong. PMID: 32638995 DOI: Item in Clipboard Cost-effectiveness of a preventive self-care health management program for community-dwelling older adults: a randomised controlled trial Arkers Kwan Ching Wong et al. Age Ageing . 2020 (...) provide some evidence to suggest that the addition of a home-based, preventive self-care health management program may have effects on cost outcomes for community-dwelling older adults in Hong Kong. Keywords: community-dwelling older adults; cost-effectiveness; self-care; self-efficacy. © The Author(s) 2020. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. Similar articles Lewis H

2020 EvidenceUpdates

8. Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Addendum to Commission A19-70

with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This adjusted indirect comparison (see Figure 1) was used for the benefit assessment. In its dossier [2], the company had presented analyses for the outcomes “serious adverse events (SAEs)” and “discontinuation due to adverse events (AEs)”. The results of these outcomes contained events that can be both symptoms of the underlying disease (...) (IQWiG) - 2 - 2 Assessment The company had presented analyses on the basis of an indirect comparison (see Figure 1) in its dossier for the assessment of ivacaftor in combination with tezacaftor/ivacaftor in patients with CF aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. For the outcomes “SAEs” and “discontinuation due to AEs”, the company had shown analyses that contained events that form part of the symptoms of the underlying disease or that can be both side

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

9. Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Addendum to Commission A19-65

]. In its dossier [2], the pharmaceutical company (hereinafter referred to as “the company”) presented results of the randomized controlled trials (RCTs) VX08-770-102 and VX08-770-103 for the assessment of the added benefit of ivacaftor in the treatment of cystic fibrosis in patients aged 6 years and older and weighing 25 kg or more who have the G551D gating mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These studies were included in the benefit assessment (...) , and no information at all on prior and concomitant medication for the relevant subpopulation of the VX08-770-103 study. Hence, the certainty of conclusions of the study results was reduced both for conclusions on patients aged 12 years and older based on the VX08-770-102 study and for children between 6 and 11 years of age based on the VX08-770-103 study. In its comments, the company presented supplementary information on concomitant antibiotic treatment in the studies VX08-770-102 and VX08-770-103, which went

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

10. Ivacaftor (combination with tezacaftor/ivacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Addendum to Commission A19-71

Table 3: Table of the company from the comments: results of the VX14-661-110 study for patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene 9 Addendum A20-06 Version 1.0 Ivacaftor – Addendum to Commission A19-71 30 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - v - List of figures Page Figure 1: Treatment sequences of the VX14-661-108 study and analysis groups of the VX14-661-110 extension study 4 Addendum A20-06 Version 1.0 (...) (CF) aged 12 years and older who are heterozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Due to the treatment duration of only 8 weeks, the study was not included in the benefit assessment, but the short-term results were presented as supplementary information. For the outcome “serious adverse events (SAEs)”, the company had presented analyses that included events that can be both symptoms of the underlying disease and side effects

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Serious harms with long-term PPI use in older adults

groups all agree that they should be prescribed at the lowest dose and for the shortest duration appropriate to the condition treated. However, PPI use continues to expand. Between 2000 and 2018 BC’s population grew by 20%, but use of PPIs increased by 257%. In 2018, 442,559 British Columbians (9% of the population) filled at least one prescription for a PPI. 1 Long-term use of PPIs in older adults We examined use of PPIs from 2008-2018 in people age 65 or older who filled a PPI prescription in BC (...) that net benefits exceed harms during long-term use in older people. Y et despite multiple signals of serious harm, 88% of people over age 65 taking PPIs in BC during 2018 had long-term exposure. Associations detected in observational studies are not proof of causation, but insisting on RCT evidence for fatal and serious adverse events from medication use contravenes modern stan- dards in pharmacovigilance. The standard levels of evidence expected to confirm treatment benefits are not equally appropri

2020 Therapeutics Letter

12. AGS Position Statement: Resource Allocation Strategies and Age-Related Considerations in the COVID-19 Era and Beyond

of the American Geriatrics Society (AGS). It is intended to inform stakeholders including hospitals, health systems, and policymakers about ethical considerations to consider when developing strategies for allocating scarce resources during an emergency involving older adults. Members of the AGS Ethics Committee collaborated with interprofessional experts in ethics, law, nursing, and medicine (including geriatrics, palliative care, emergency medicine, and pulmonology/critical care) to conduct a structured (...) Strategies and Age-Related Considerations in the COVID-19 Era and Beyond Enter PIN * × PIN Subscriprion Subscription is completed successfully. Click OK button to go to MyLibrary page. Product Type : Guidelines, Recommendations & Position Statements Language : ENGLISH Publisher : American Geriatrics Society Year of publication : 2020 DESCRIPTION Disclaimer These recommendations published by The American Geriatrics Society (AGS) incorporate data obtained from a literature review of the most recent studies

2020 American Geriatrics Society

13. Frailty status predicts futility of cardiopulmonary resuscitation in older adults

escalation plans, as it becomes more widespread, larger scale observations using prospective assessments of frailty may become feasible. Keywords: cardiac-arrest; cardiopulmonary resuscitation; frailty; older people; resuscitation. © The Author(s) 2020. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. Similar articles Wharton C, King E, MacDuff A. Wharton C, et al. Resuscitation. 2019 Oct (...) Permalink Copy Page navigation Age Ageing Actions . 2020 Jun 5;afaa104. doi: 10.1093/ageing/afaa104. Online ahead of print. Frailty status predicts futility of cardiopulmonary resuscitation in older adults , , , , Affiliations Expand Affiliations 1 North Bristol NHS Trust, University College London, London, UK. 2 North Bristol NHS Trust, Bristol, UK. 3 Gloucestershire Hospitals, NHS Foundation Trust, Gloucester, UK. 4 North Bristol NHS Trust, University of Bristol, Bristol, UK. PMID: 32500916 DOI: Item

2020 EvidenceUpdates

14. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis

study. Am J Med. 2014;127:530-537.e3. Kampfen P, Mean M, Limacher A, et al. Risk of falls and bleeding in elderly patients with acute venous thromboembolism. J Intern Med. 2014;276:378-386. Johnson SA, Eleazer GP, Rondina MT. Pathogenesis, diagnosis, and treatment of venous thromboembolism in older adults. J Am Geriatr Soc. 2016;64:1869-1878. Sterne JA, Bodalia PN, Bryden PA, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Am Geriatr Soc Actions . 2020 May 22. doi: 10.1111/jgs.16549. Online ahead of print. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis , , , , , Affiliations Expand Affiliations 1 Division of Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. 2 Division of Cardiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 3 Evidence-based

2020 EvidenceUpdates

15. Psychotherapy for Depression Across Different Age Groups: A Systematic Review and Meta-analysis

duplicates, 16 756 records were screened and 2608 full-text articles were screened. Of these, 366 trials (36 702 patients) with 453 comparisons between a therapy and a control condition were included in the qualitative analysis, including 13 (3.6%) in children (13 years and younger), 24 (6.6%) in adolescents (≥13 to 18 years), 19 (5.2%) in young adults (≥18 to 24 years), 242 (66.1%) in middle-aged adults (≥24 to 55 years), 58 (15.8%) in older adults (≥55 to 75 years), and 10 (2.7%) in older old adults (...) in middle-aged adults. No significant difference was found between older adults (g = 0.66; 95% CI, 0.51-0.82) and those in older old adults (g = 0.97; 95% CI, 0.42-1.52). The outcomes should be considered with caution because of the suboptimal quality of most of the studies and the high levels of heterogeneity. However, most primary findings proved robust across sensitivity analyses, addressing risk of bias, target populations included, type of therapy, diagnosis of mood disorder, and method of data

2020 EvidenceUpdates

16. Conservative vs Surgical Treatment of Impacted Femoral Neck Fracture in Patients 75 Years and Older

Copy Actions Cite Share Permalink Copy Page navigation J Am Geriatr Soc Actions . 2020 May 15. doi: 10.1111/jgs.16535. Online ahead of print. Conservative vs Surgical Treatment of Impacted Femoral Neck Fracture in Patients 75 Years and Older , , , , , Affiliations Expand Affiliation 1 Department of Orthopaedics, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. PMID: 32413174 DOI: Item in Clipboard Conservative vs Surgical Treatment of Impacted Femoral Neck Fracture in Patients 75 (...) Years and Older Peiran Wei et al. J Am Geriatr Soc . 2020 . Show details J Am Geriatr Soc Actions . 2020 May 15. doi: 10.1111/jgs.16535. Online ahead of print. Authors , , , , , Affiliation 1 Department of Orthopaedics, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. PMID: 32413174 DOI: Item in Clipboard Full-text links Cite Abstract Objective: To evaluate the safety and effectiveness of conservative treatment (CST), internal fixation (IF), and hemiarthroplasty (HA) in treating

2020 EvidenceUpdates

17. Dementia and mild cognitive impairment in prisoners aged over 50 years in England and Wales: a mixed-methods study Full Text available with Trip Pro

Dementia and mild cognitive impairment in prisoners aged over 50 years in England and Wales: a mixed-methods study Dementia and mild cognitive impairment in prisoners aged over 50 years in England and Wales: a mixed-methods study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study found a relatively high prevalence of dementia/mild cognitive impairment in prisons and it developed a care pathway and training materials for staff and prisoners. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , & . Katrina Forsyth 1 , Leanne Heathcote 1 , Jane Senior 1, * , Baber Malik 1 , Rachel Meacock 1 , Katherine Perryman 1 , Sue Tucker 1 , Rachel

2020 NIHR HTA programme

18. Medication management in older people: the MEMORABLE realist synthesis Full Text available with Trip Pro

Medication management in older people: the MEMORABLE realist synthesis Medication management in older people: the MEMORABLE realist synthesis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1

2020 NIHR HTA programme

19. Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V

report is the assessment of the added benefit of ivacaftor in combination with tezacaftor/ivacaftor in comparison with the appropriate comparator therapy (ACT) best supportive care (BSC) in patients with cystic fibrosis (CF) aged 12 years and older who are heterozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The patients have one of the following mutations on the second allele: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A?G, S945L, S977F (...) , R1070W, D1152H, 2789+5G?A, 3272-26A?G and 3849+10kbC?T. Table 2: Research questions of the benefit assessment of ivacaftor + tezacaftor/ivacaftor + BSC Therapeutic indication ACT a Patients with cystic fibrosis aged 12 years and older who are heterozygous for the F508del mutation and have one of the following 14 mutations on the second allele in the CFTR gene b : P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A?G, S945L, S977F, R1070W, D1152H, 2789+5G?A, 3272-26A?G and 3849+10kbC?T BSC a: Presentation

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V

benefit of ivacaftor in combination with tezacaftor/ivacaftor in comparison with the appropriate comparator therapy (ACT) lumacaftor/ivacaftor in patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Table 2: Research question of the benefit assessment of ivacaftor + tezacaftor/ivacaftor Therapeutic indication ACT a CF patients aged 12 years and older who are homozygous (...) + tezacaftor/ivacaftor) The VX14-661-106 study was a randomized, double-blind, parallel-group study, in which patients were treated with ivacaftor + tezacaftor/ivacaftor or received matching placebo, each against the background of concomitant symptomatic treatment. The study included patients aged 12 years and older who were homozygous for the F508del mutation in the CFTR gene and who had confirmed diagnosis of CF defined as a sweat chloride value of = 60 mmol/L. In addition, the patients had to have

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)